Genmab Q4 2025 Earnings Report: Innovation Push Drives Profit Surge
Genmab A/S (Nasdaq: GMAB) released its full-year 2025 financial results, demonstrating the company’s improved operational execution. Total revenue reached $3.72...
Genmab A/S (Nasdaq: GMAB) released its full-year 2025 financial results, demonstrating the company’s improved operational execution. Total revenue reached $3.72...
InMode Ltd (NASDAQ: INMD) reported its financial results for the fourth quarter and full year ended December 31, 2025, showing...
Zimmer Biomet Holdings, Inc. (NYSE: ZBH) closed at $93.60, up 4.3% on the day, after reporting fourth-quarter and full-year 2025...
Roivant Sciences (Nasdaq: ROIV) reported its financial results for the fiscal third quarter ended December 31, 2025, underscored by positive...
Roivant Sciences (Nasdaq: ROIV) on Friday reported its financial results for the fiscal third quarter ended December 31, 2025, revealing...